Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Fabry-Anderson's disease]

C Andratschke

    Fortschritte Der Medizin
    |December 4, 1975
    PubMed
    Summary

    Fabry's disease, an inherited metabolic disorder, involves abnormal ceramide trihexoside accumulation, affecting organs like the kidneys and heart. Diagnosis is confirmed via enzyme activity tests and organ biopsy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [Stomach ulcer in elderly patients].

    Schwestern Revueยท1976
    See all related articles

    Area of Science:

    • Biochemistry
    • Genetics
    • Nephrology

    Context:

    • Fabry's disease, initially viewed as a dermatological condition, is now understood as a systemic inherited metabolic disorder.
    • The disease is characterized by the accumulation of globotriaosylceramide (Gb3) in various organs, including the epidermis, kidneys, heart, and blood vessels.
    • Clinical manifestations include characteristic skin lesions, corneal opacities (cornea verticillata), and progressive kidney damage.

    Purpose:

    • To provide an overview of Fabry's disease, highlighting its metabolic basis and clinical presentation.
    • To discuss diagnostic methods, including biochemical analysis and kidney biopsy.
    • To review current therapeutic approaches, noting the experimental nature of causal treatments.

    Summary:

    • Fabry's disease results from a genetic defect leading to the accumulation of globotriaosylceramide (Gb3) due to deficient alpha-galactosidase A activity.
    • Key diagnostic indicators include reduced alpha-galactosidase activity in blood and increased Gb3 excretion in urine.
    • While effective causal therapies are still under development, various treatment strategies are being explored.

    Impact:

    • Enhances understanding of Fabry's disease as a complex metabolic disorder with multi-organ involvement.
    • Clarifies diagnostic pathways, aiding clinicians in timely and accurate disease identification.
    • Highlights the ongoing research into novel therapies, offering hope for future treatment advancements.

    Related Experiment Videos